Flat PV fee possible as EU rewrites earlier ‘disproportionate’ proposals
This article was originally published in Scrip
Executive Summary
Drug companies in the EU could be looking at paying the European Medicines Agency a flat fee – presumably annually – to cover the agency’s responsibilities under the new EU pharmacovigilance legislation.